Iron Deficiency Anemia (IDA)


Get Dexur’s Personalized Hospital Specific Presentation on Quality, Safety, Compliance & Education

No Image

By: James Pitt  Jul. 04, 2018

Iron deficiency anemia (IDA) is a condition in which the body has too little iron to properly supply red blood cells, leading to fatigue and weakness. According to the Merck Manual, blood loss is the most common cause of IDA. About 70% of the body's iron is already in red blood cells, rather than stored in reserve, so patients may require iron supplementation after major blood loss.

Read more

No Image

By: James Pitt  Jun. 14, 2018

Anemia is a common complication of chronic kidney disease and renal failure. Gaweda et. al (2014) write that “Anemia in chronic kidney disease (CKD) is primarily a consequence of insufficient erythropoietin (EPO) production.” EPO is a hormone produced primarily in the kidneys, which stimulates red blood cell production in bone marrow. Recombinant human EPO (rHuEPO) can help make up for the lack of EPO production, but rHuEPO alone may not alleviate anemia in all patients, because other components (like iron) are also necessary for normal red blood cell production. According to Nissenson and Strobos (1999), “Deficient available iron is the most common cause of initial poor response to rHuEPO.”

Read more

By: James Pitt  May. 15, 2018

Dexur has covered a variety of disease burden metrics across states. Here is a summary of key articles by disease area.

Read more

No Image

By: James Pitt  May. 01, 2018

Iron deficiency anemia (IDA) is the most common nutritional deficiency worldwide. Symptoms include fatigue, weakness, and pale skin. Diet and gastrointestinal problems can cause IDA. But blood loss is more common. As the Merck Manual notes, “Iron deficiency is one of the most common causes of anemia, and blood loss is the most common cause of iron deficiency in adults.”

Read more

No Image

By: Jeffrey Maser  Feb. 26, 2018

The FDA’s recent approval of label expansion for Ferahame (ferumoxytol injection), by AMAG Pharmaceuticals, could be an opportunity for hospitals to positively impact patient length of stay outcomes. Feraheme, which was previously approved only for Chronic Kidney Disease (CKD) has now been expanded to all patients with Iron Deficiency Anemia (IDA). The company’s press release following label expansion states a few key points:

Read more